Targets › DYSTROPHIN
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Jan 2027.
Open in Phaseline: the race on DYSTROPHIN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Daiichi Sankyo | DS-5141b (Renadirsen) Antisense oligonucleotide targeting dystrophin pre-mRNA | DYSTROPHIN | Phase 2 | Duchenne Muscular Dystrophy | Jan 2027 |
Duchenne Muscular Dystrophy (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.